GlassScriptPhysician profile
Kate R Gerber
NPI 1750600359
$15,964.03
in general payments reported to CMS, 2019-2025
35 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $674 · 2021: $1,000 · 2022: $9,453 · 2023: $1,125 · 2024: $1,489 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,874 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,874.17 |
| Education | $121.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $8,205.68 | 2021-2025 | Opzelura |
| Abbvie INC. | $1,203.02 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $833.65 | 2019-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $747.32 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $676.70 | 2019-2025 | Ilumya, Blu-U |
| Novartis Pharmaceuticals Corporation | $527.72 | 2019-2025 | |
| Ucb, INC. | $423.57 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $418.86 | 2020-2025 | |
| Lilly USA, LLC | $364.70 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $336.53 | 2019-2025 | Anzupgo, Adbry |
| Biofrontera INC. | $334.31 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $310.75 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $223.70 | 2019-2025 | |
| Galderma Laboratories, L.P. | $136.74 | 2021-2025 | Aklief, Twyneo, Oracea |
| E.R. Squibb & Sons, L.L.C. | $134.58 | 2022-2024 | Sotyktu |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $131.68 | 2020-2024 | Affinity |
| Kerecis Limited | $125.48 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Merz North America, INC. | $113.45 | 2019-2021 | |
| Smith+Nephew, INC. | $100.30 | 2020-2022 | |
| Allergan, INC. | $87.54 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $75.58 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $62.15 | 2019-2023 | Valchlor |
| Vyne Pharmaceuticals INC. | $58.25 | 2020-2021 | |
| Dermavant Sciences, INC. | $53.02 | 2023-2024 | Vtama |
| Convatec INC. | $52.84 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $38.79 | 2023 | |
| Solta Medical, A Division of Bausch Health US, LLC | $23.44 | 2021 | |
| Aclaris Therapeutics, INC. | $22.31 | 2019 | |
| Celgene Corporation | $22.06 | 2019 | |
| Genentech USA, INC. | $21.13 | 2023 | Erivedge |
| Journey Medical Corporation | $20.83 | 2019 | |
| Almirall LLC | $20.80 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.66 | 2019 | |
| Springworks Therapeutics, INC. | $19.22 | 2025 | Gomekli |
| Sandoz INC. | $16.67 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.